PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Oct 19, 2017
SOUTH PLAINFIELD, N.J., Oct. 19, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Thursday, November 2, 2017 at 4:30 p.m. (ET) after the closing of the market. Th...
Oct 12, 2017
SOUTH PLAINFIELD, N.J., Oct. 12, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) transitioned into the pivotal part of the study evaluating the efficacy and safety of RG7916 in pediatric and adult Type 2/3 SMA pati...
Oct 3, 2017
SOUTH PLAINFIELD, N.J., Oct. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from Part 1 of the SUNFISH trial of RG7916 in Type 2/3 spinal muscular atrophy (SMA) patients.  RG7916 is part of PTC's joint development program in SMA with Roche and the SMA Foundation (SMAF). The data were presented at the 22nd Interna...
Sep 21, 2017
SOUTH PLAINFIELD, N.J., Sept. 21, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 18, 2017 it approved non-statutory stock options to purchase an aggregate of 32,500 shares of its common stock to thirteen new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component...
Sep 7, 2017
SOUTH PLAINFIELD, N.J., Sept. 7, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2017 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the Duchenne muscular dystrophy (DMD) community. The anno...
Aug 10, 2017
SOUTH PLAINFIELD, N.J., Aug. 10, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on August 7, 2017 it approved non-statutory stock options to purchase an aggregate of 31,000 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ne...
Aug 8, 2017
SOUTH PLAINFIELD, N.J., Aug. 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2017. "Since our founding nearly 20 years ago, it has been our mission to provide treatments to patients living with rare diseases who have limite...
Jul 25, 2017
SOUTH PLAINFIELD, N.J., July 25, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter financial results and provide an update on the company's business and outlook on Tuesday, August 8, 2017 at 4:30 p.m. (ET) after the closing of the market. ...
Jul 24, 2017
SOUTH PLAINFIELD, N.J., July 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Joseph McIntosh, M.D. to Senior Vice President and Head of Clinical Development. Dr. McIntosh will be responsible for all aspects of Clinical Development across PTC's portfolio. "Dr. McIntosh's extensive experience and...
Jul 18, 2017
SOUTH PLAINFIELD, N.J., July 18, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of the results of the ACT DMD trial study ataluren, the only treatment for the underlying cause of nonsense mutation Duchene muscular dystrophy (nmDMD), in the current issue of The Lancet. "There is a critical need for...
Page:
1
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue